Roche (VTX:ROG)‘s stock had its “buy” rating reissued by JPMorgan Chase & Co. in a research report issued to clients and investors on Tuesday.
A number of other equities analysts also recently commented on ROG. Goldman Sachs set a CHF 325 price target on Roche and gave the stock a “buy” rating in a research note on Monday, November 20th. Berenberg Bank set a CHF 260 price target on Roche and gave the stock a “neutral” rating in a research note on Monday, November 20th. HSBC set a CHF 205 target price on Roche and gave the company a “sell” rating in a research note on Tuesday, November 21st. Baader Bank set a CHF 256 target price on Roche and gave the company a “buy” rating in a research note on Tuesday, November 21st. Finally, Liberum Capital set a CHF 279 target price on Roche and gave the company a “buy” rating in a research note on Wednesday, November 22nd. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of CHF 255.05.
Roche (VTX:ROG) traded down CHF 1.20 during trading hours on Tuesday, reaching CHF 219.60. The company had a trading volume of 3,740,000 shares, compared to its average volume of 2,090,000. The firm has a market capitalization of $191,160.00 and a P/E ratio of 21.87. Roche has a fifty-two week low of CHF 214.30 and a fifty-two week high of CHF 273.
WARNING: This piece of content was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.thestockobserver.com/2018/03/20/roche-rog-receives-buy-rating-from-jpmorgan-chase-co.html.
Roche Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.